All articles tagged with #t cells
Scientists at the University of Southampton developed a four-armed antibody that enhances T cell activation by clustering immune receptors, significantly boosting the immune response against cancer in laboratory tests, offering a promising new approach for cancer immunotherapy.
A mouse study demonstrates that an experimental mRNA treatment can rejuvenate immune cells, specifically T cells, potentially improving immune response in aging, but further research is needed to assess its applicability in humans.
MIT researchers have developed a method to temporarily boost immune function in aging by reprogramming liver cells to produce T-cell supporting signals, improving immune responses and potentially helping older adults stay healthier longer.
A study demonstrates that a twice-weekly cocktail of three messenger RNAs can rejuvenate aged immune cells in mice, particularly T cells, enhancing their response to vaccines and cancer therapies, by targeting T cells through the liver to counteract age-related decline and thymus degradation.
Researchers at MIT and the Broad Institute have developed a method using mRNA to temporarily program liver cells, creating a 'factory' that produces T-cell survival factors, which rejuvenates the immune system in aged mice and enhances their response to vaccines and cancer treatments. This approach could potentially help maintain immune health in humans as they age.
A recent study challenges the traditional view that inflammation ('inflammaging') is the main driver of immune decline with age, suggesting instead that aging reprograms T cells independently of inflammation, which could impact vaccine effectiveness and aging treatments.
This study uses multi-omic profiling over two years to reveal that in healthy adults, immune system changes with age are characterized by stable, transcriptional reprogramming of T cells, a progressive TH2 bias in memory T cells, and altered B cell responses to influenza vaccination, with minimal influence from chronic CMV infection or systemic inflammation prior to advanced age.
Researchers have developed a technology to reprogram rogue T cells into protective Treg cells, demonstrating targeted therapy for autoimmune diseases like pemphigus vulgaris, inflammatory bowel disease, and graft-versus-host disease in mouse models, potentially leading to safer, personalized treatments.
A study published in Nature shows that pregnancy and breastfeeding promote the accumulation of specialized immune cells called CD8+ T cells in the breast, which can reduce the risk of breast cancer and improve survival rates, with effects lasting for decades.
Research shows that breastfeeding leaves long-lasting immune cells in the breast, particularly CD8+ T-cells, which help protect against breast cancer, especially aggressive types like triple-negative breast cancer. These immune cells remain for decades and are associated with better outcomes, suggesting potential for new preventive strategies and therapies.
Research from the Doherty Institute reveals that lymph nodes play a crucial role in training immune cells to fight cancer, suggesting that removing them during surgery might weaken immunotherapy effectiveness. Preserving lymph nodes could enhance immune responses and improve treatment outcomes for cancer patients.
Scientists at the Salk Institute found that bile acids, especially ursodeoxycholic acid (UDCA), influence immune cell function in the liver and could enhance immunotherapy effectiveness against liver cancer, with UDCA supplements already approved for other liver conditions offering a promising therapeutic avenue.
Scientists from Ohio State University have discovered that T-cell exhaustion in cancer is caused by a stress response called TexPSR, driven by misfolded proteins. Blocking this pathway restores T-cell function and enhances immunotherapy effectiveness across various cancer types, offering a new approach to improve cancer treatments.
A study suggests ALS may be an autoimmune disease where CD4+ T cells attack neuron proteins, with patients showing different survival times based on their immune response; boosting protective T cells could lead to new treatments.
The study identifies C9orf72 as a major autoantigen targeted by CD4+ T cells in ALS patients, with responses skewed towards an anti-inflammatory profile, especially in those with longer survival, suggesting a potential protective immune component in ALS progression.